DOCSLIB.ORG

Exposure Protocols

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Exposure Protocols Exposure Protocols Contents Introduction .................................................................................................................................................. 4 Flowchart – First Aid and Medical Response Protocol for Human Blood and/or Tissues and MDRO Incidents ........................................................................................................................................................ 6 Medical Surveillance for Primary Blood Products ....................................................................................... 8 Human Immunodeficiency Virus (HIV);................................................................................................. 8 Hepatitis B Virus (HBV); ........................................................................................................................ 8 Hepatitis C Virus (BVC); ......................................................................................................................... 8 Treponema pallidum ............................................................................................................................. 8 Human T-Lymphotropic Virus (HTLV); ................................................................................................ 12 Leptospira interrogans; ....................................................................................................................... 12 Creutzfedlt-Jacob agent, Kuru agent .................................................................................................. 12 Medical Surveillance Breast Milk .............................................................................................................. 15 Human Immunodeficiency Virus (HIV);............................................................................................... 15 Human T-Lymphotropic Virus (HTLV); ................................................................................................ 15 Cytomegalovirus (CMV); ..................................................................................................................... 15 Creutzfedlt-Jacob agent, Kuru agent .................................................................................................. 15 Medical Surveillance Inventory Bacteria ................................................................................................... 21 Streptococcus Group A (S. pyogenes); ................................................................................................ 21 Staphylococcus intermedius; ............................................................................................................... 21 Staphylococcus hyicus; ........................................................................................................................ 21 Streptococcus Group B (S. agalactiae) ................................................................................................ 21 Streptococcus Group C (S. zooepidemicus, S. equi, and S. dysgalactiae); ........................................... 24 Streptococcus Group D;....................................................................................................................... 24 Streptococcus pneumoniae; ................................................................................................................ 24 Candida albicans ................................................................................................................................. 24 Listeria monocytogenes; ..................................................................................................................... 29 Nocardia spp.; ..................................................................................................................................... 29 Streptococcus salivarius (S. viridans); ................................................................................................. 29 SEM 20.25.1 Exposure Protocols – Medical Surveillance Page 1 of 92 Revised: January 26, 2017 Pseudomonas aeruginosa ................................................................................................................... 29 Proteus spp.; ........................................................................................................................................ 34 Bacillus cereus; .................................................................................................................................... 34 Citrobacter diversus; ........................................................................................................................... 34 Enterobacter spp. (E. cloacae, E. aerogenes) ...................................................................................... 34 Haemophilus influenzae; ..................................................................................................................... 39 Pasteurella sp.; .................................................................................................................................... 39 Salmonella enterica spp.; .................................................................................................................... 39 Staphylococcus aureus (MRSA, MSSA, VISA, hVISA, VRSA) ................................................................ 39 Bordatella bronchiseptica; .................................................................................................................. 46 Serratia sp.; ......................................................................................................................................... 46 Klebsiella spp.; ..................................................................................................................................... 46 Vancomycin-resistant Enterococci (VRE) ............................................................................................ 46 Medical Surveillance Sewage Bacteria ...................................................................................................... 54 Legionella pneumophila; ..................................................................................................................... 54 Mycobacterium spp.; .......................................................................................................................... 54 Shigella spp.; ....................................................................................................................................... 54 Helicobacter pylori .............................................................................................................................. 54 Escherichia coli (enterotoxigenic); ...................................................................................................... 59 Escherichia coli (uropathogenic); ........................................................................................................ 59 Escherichia coli (entero-hemorrhagic), ............................................................................................... 59 Escherichia coli (septicemia causing) .................................................................................................. 59 Staphylococcus aureus (MRSA, MSSA, VISA, hVISA, VRSA); ................................................................ 62 Salmonella enterica spp.; .................................................................................................................... 62 Aeormonas hydrophilia; ...................................................................................................................... 62 Campylobacter coli. ............................................................................................................................. 62 Clostridium difficile; ............................................................................................................................ 69 Clostridium botulinum; ........................................................................................................................ 69 Yersinia enteracolitica; ........................................................................................................................ 69 Campylobacter jejuni .......................................................................................................................... 69 Clostridium perfringens; ...................................................................................................................... 76 Klebsiella spp.; ..................................................................................................................................... 76 SEM 20.25.1 Exposure Protocols – Medical Surveillance Page 2 of 92 Revised: January 26, 2017 Actineobacter spp. .............................................................................................................................. 76 Medical Surveillance Sewage Viruses ........................................................................................................ 80 Norovirus; ........................................................................................................................................... 80 Adenovirus serotypes 1-5, and 7; ....................................................................................................... 80 Adenovirus serotypes 40 and 41; ....................................................................................................... 80 Hepatitis A Virus .................................................................................................................................
Load more

Recommended publications
  • USMLE – What's It
    Purpose of this handout Congratulations on making it to Year 2 of medical school! You are that much closer to having your Doctor of Medicine degree. If you want to PRACTICE medicine, however, you have to be licensed, and in order to be licensed you must first pass all four United States Medical Licensing Exams. This book is intended as a starting point in your preparation for getting past the first hurdle, Step 1. It contains study tips, suggestions, resources, and advice. Please remember, however, that no single approach to studying is right for everyone. USMLE – What is it for? In order to become a licensed physician in the United States, individuals must pass a series of examinations conducted by the National Board of Medical Examiners (NBME). These examinations are the United States Medical Licensing Examinations, or USMLE. Currently there are four separate exams which must be passed in order to be eligible for medical licensure: Step 1, usually taken after the completion of the second year of medical school; Step 2 Clinical Knowledge (CK), this is usually taken by December 31st of Year 4 Step 2 Clinical Skills (CS), this is usually be taken by December 31st of Year 4 Step 3, typically taken during the first (intern) year of post graduate training. Requirements other than passing all of the above mentioned steps for licensure in each state are set by each state’s medical licensing board. For example, each state board determines the maximum number of times that a person may take each Step exam and still remain eligible for licensure.
    [Show full text]
  • WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/05 (2006.01) A61P 31/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/CA20 14/000 174 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 4 March 2014 (04.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13/790,91 1 8 March 2013 (08.03.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: LABORATOIRE M2 [CA/CA]; 4005-A, rue kind of regional protection available): ARIPO (BW, GH, de la Garlock, Sherbrooke, Quebec J1L 1W9 (CA). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: LEMIRE, Gaetan; 6505, rue de la fougere, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Sherbrooke, Quebec JIN 3W3 (CA).
    [Show full text]
  • 2012 Case Definitions Infectious Disease
    Arizona Department of Health Services Case Definitions for Reportable Communicable Morbidities 2012 TABLE OF CONTENTS Definition of Terms Used in Case Classification .......................................................................................................... 6 Definition of Bi-national Case ............................................................................................................................................. 7 ------------------------------------------------------------------------------------------------------- ............................................... 7 AMEBIASIS ............................................................................................................................................................................. 8 ANTHRAX (β) ......................................................................................................................................................................... 9 ASEPTIC MENINGITIS (viral) ......................................................................................................................................... 11 BASIDIOBOLOMYCOSIS ................................................................................................................................................. 12 BOTULISM, FOODBORNE (β) ....................................................................................................................................... 13 BOTULISM, INFANT (β) ...................................................................................................................................................
    [Show full text]
  • Emerging Infectious Diseases Objectives What
    12/2/2015 EMERGING INFECTIOUS DISEASES What could be emerging in North Dakota? TRACY K. MILLER, PHD, MPH STATE EPIDEMIOLOGIST [email protected] OBJECTIVES 1. Identify new or re-emerging infections 2. Identify ways outside agencies can help the health department monitor for disease 3. Determine what education needs are available. 2 WHAT ARE "EMERGING" INFECTIOUS DISEASES? Infectious diseases whose incidence in humans has increased in the past two decades or threatens to increase in the near future have been defined as "emerging." These diseases, which respect no national boundaries, include: • New infections resulting from changes or evolution of existing organisms • Known infections spreading to new geographic areas or populations • Previously unrecognized infections appearing in areas undergoing ecologic transformation 3 1 12/2/2015 WHAT ARE RE-EMERGING INFECTIOUS DISEASES? Any condition, usually an infection, that had decreased in incidence in the global population and was brought under control through effective health care policy and improved living conditions, reached a nadir, and, more recently, began to resurge as a health problem due to changes in the health status of a susceptible population. 4 REPORTABLE CONDITIONS 5 CDC’S LIST OF EIDS • malaria • drug-resistant infections (antimicrobial resistance) • Marburg hemorrhagic fever • bovine spongiform encephalopathy (Mad cow disease) & variant Creutzfeldt-Jakob disease (vCJD) • measles • campylobacteriosis • meningitis • Chagas disease • monkeypox • cholera • MRSA (Methicillin Resistant
    [Show full text]
  • Report June 2
    COMMUNICABLE DISEASES • ISSN 1361 - 1887 Provisional Summary 2003 Northern Ireland Edition Vol 12 No 13 COMMUNICABLE DISEASES ISSN 1361 - 1887 Introduction This report summarises the main trends in communicable disease in Northern Ireland during 2003. It is primarily based on laboratory reports forward to CDSC (NI) and information supplied by Consultants in Communicable Disease Control. This is a more detailed annual summary than in previous years and replaces our annual report. The data for 2003 should be regarded as provisional to allow for late reporting of results and further typing of organisms. CDSC (NI) is extremely grateful to colleagues in Trusts and Boards for providing timely data and information on a wide range of infections and communicable disease issues. This summary can also be downloaded from our website http://www.cdscni.org.uk Contributing Laboratories Information Altnagelvin Mater Editorial Team: CDSC (NI) Antrim Musgrave Park Belfast City Hospital Belfast City Regional Mycology Dr Brian Smyth Lisburn Road, Belfast, BT9 7AB Belvoir Park Regional Virus Audrey Lynch N.Ireland Causeway Royal Victoria Dr Julie McCarroll Telephone: 028 9026 3765 Craigavon Tyrone County Dr Hilary Kennedy Fax: 028 9026 3511 Daisyhill Ulster Ruth Fox Email: [email protected] Erne Julie Boucher COMMUNICABLE DISEASES: Provisional Summary 1 Contents 1 Gastrointestinal Infections 3 Foodborne and Gastrointestinal outbreaks: 2003 2 Imported Infections 9 3 Human Brucellosis in Northern Ireland, 2003 13 4 Enhanced Surveillance of Influenza in Northern Ireland 15 5 Enhanced Surveillance of Meningococcal Disease 19 6 Enhanced Surveillance of Tuberculosis 23 7 Legionella Infections 27 8 Hepatitis 29 9 HIV and AIDS 33 10 Syphilis Outbreak in Northern Ireland 2001-2003 37 11 Childhood Vaccination Programme 41 Appendix 1 – Trends in Specific Reported Pathogens Appendix 2 – Notifications of Infections Diseases COMMUNICABLE DISEASES: Provisional Summary 2 1 Gastrointestinal infections Notifications of food poisoning increased steadily from1991 to 2000.
    [Show full text]
  • Middle East Respiratory Syndrome Coronavirus Update Legionnaires' Disease Outbreak in Shelby County
    WINTER IS NORO- ISSUE 1 VOLUME 7 2014 VIRUS SEASON ....... 2 ASSESSING DISPENS- ING ACCURACY FOR MEDICAL COUNTER- MEASURE EXCERCIS- ES .......................... 2 ONE HEALTH: WILD PIGS, HUNTERS AND BRUCELLOSIS……...3 WATCHING OUT FOR FLU ........................ 3 THE LIST OF REPORT- ABLE DISEASES AND EVENTS .................. 3 Tennessee TENNESSEE DEPARTMENT OF HEALTH COMMISSIONER JOHN J. DREYZEHNER, MD, MPH epi-news Legionnaires’ Disease Outbreak in Shelby County In June 2013, the Shelby County Health areas and to conduct environmental sam- Department received multiple reports of pling, testing and remediation using estab- Legionnaires’ disease among inpatients at lished methodologies. The investigators local hospitals. Health department epide- also initiated active surveillance for le- miologists quickly responded, conducting gionellosis and soon found four more cases detailed interviews with the patients using sharing this exposure. an interview form they had adapted with questions specific to Shelby County expo- Legionnaires’ disease is a form of commu- sures. nity-acquired pneumonia caused by Le- gionella species. A less severe form of Interviews with the first seven identified legionellosis is known as Pontiac fever. patients revealed that five of them had fre- Legionella bacteria are ubiquitous in the quented the same hot tub and steam room environment and thrive in warm, manmade conditions are predisposing factors. Most in a fitness center within two to ten days water systems. People can become infected cases occur sporadically
    [Show full text]
  • | Oa Tai Ei Rama Telut Literatur
    |OA TAI EI US009750245B2RAMA TELUT LITERATUR (12 ) United States Patent ( 10 ) Patent No. : US 9 ,750 ,245 B2 Lemire et al. ( 45 ) Date of Patent : Sep . 5 , 2017 ( 54 ) TOPICAL USE OF AN ANTIMICROBIAL 2003 /0225003 A1 * 12 / 2003 Ninkov . .. .. 514 / 23 FORMULATION 2009 /0258098 A 10 /2009 Rolling et al. 2009 /0269394 Al 10 /2009 Baker, Jr . et al . 2010 / 0034907 A1 * 2 / 2010 Daigle et al. 424 / 736 (71 ) Applicant : Laboratoire M2, Sherbrooke (CA ) 2010 /0137451 A1 * 6 / 2010 DeMarco et al. .. .. .. 514 / 705 2010 /0272818 Al 10 /2010 Franklin et al . (72 ) Inventors : Gaetan Lemire , Sherbrooke (CA ) ; 2011 / 0206790 AL 8 / 2011 Weiss Ulysse Desranleau Dandurand , 2011 /0223114 AL 9 / 2011 Chakrabortty et al . Sherbrooke (CA ) ; Sylvain Quessy , 2013 /0034618 A1 * 2 / 2013 Swenholt . .. .. 424 /665 Ste - Anne -de - Sorel (CA ) ; Ann Letellier , Massueville (CA ) FOREIGN PATENT DOCUMENTS ( 73 ) Assignee : LABORATOIRE M2, Sherbrooke, AU 2009235913 10 /2009 CA 2567333 12 / 2005 Quebec (CA ) EP 1178736 * 2 / 2004 A23K 1 / 16 WO WO0069277 11 /2000 ( * ) Notice : Subject to any disclaimer, the term of this WO WO 2009132343 10 / 2009 patent is extended or adjusted under 35 WO WO 2010010320 1 / 2010 U . S . C . 154 ( b ) by 37 days . (21 ) Appl. No. : 13 /790 ,911 OTHER PUBLICATIONS Definition of “ Subject ,” Oxford Dictionary - American English , (22 ) Filed : Mar. 8 , 2013 Accessed Dec . 6 , 2013 , pp . 1 - 2 . * Inouye et al , “ Combined Effect of Heat , Essential Oils and Salt on (65 ) Prior Publication Data the Fungicidal Activity against Trichophyton mentagrophytes in US 2014 /0256826 A1 Sep . 11, 2014 Foot Bath ,” Jpn .
    [Show full text]
  • Copyrighted Material
    INDEX A American hemorrhagic fevers: Antibiotic action; Drug resistance; Α-dystroglycan, 301 Argentine, 16–17, 35, 279–280; Immune system; specifi c disease Abrus precatorius, 689 Bolivian, 277, 280, 287–288; Antiviral agents: AZT (zidovudine), Acid-fast bacteria, 212 Brazilian, 277, 281; overview of, 13, 32, 38, 48, 340–341, 355, 356; Active Bacterial Core (ABCs) 274, 274–279, 282–286; treatment, blocking synthesis of bacterial surveillance, 240 prevention, surveillance of, 275, RNA, 47; categories of HIV, 356; Active immunization, 465 287–289; Venezuelan, 277, 280–281 dengue fever, DHF, and DSS, 327– Acute glomerulonephritis, 119, 121, 126 Amoeba histolytica, 34 328; description of, 32; HAART, Acute Q fever, 15 Anaplasma phagocytophilum, 36, 76, 77, 48, 356–357, 382; hepatitis C virus Adaptive immunity, 40–42 84, 85, 86, 89, 90, 640–641, 645 (HCV), 391, 402–403; HHV-8 Adenocarcinoma of the lower Anaplasmosis, 552 and KS treatment using, 380–382; esophagus, 167–168 Andes virus, 442 SARS, 466–467. See also Interferons Adenovirus infection, 646–647 Anemia, 176, 528 Arenaviridae, 300 Aedes aegypti mosquito, 318, 322, Angiotensin-converting enzyme 2 Argentine hemorrhagic fever, 16–17, 328–329 (ACE-2), 463–464 35, 279–280 Aedes albopictus mosquito, 318, 322–323 Anopheles mosquitoes, 35, 525, 526, 537 Artemisinin, 535 Age-related immune system defects, Anthrax, 15, 670, 674–676 “Asian Flu” pandemic (type H2N2) 639–640, 642 Antibiotic action, 226, 228–229, 235– [1957], 413 Agglutination, 44 237. See also Antimicrobial agents; Aspergillus fungi,
    [Show full text]
  • INFECTIOUS DISEASES of ETHIOPIA Infectious Diseases of Ethiopia - 2011 Edition
    INFECTIOUS DISEASES OF ETHIOPIA Infectious Diseases of Ethiopia - 2011 edition Infectious Diseases of Ethiopia - 2011 edition Stephen Berger, MD Copyright © 2011 by GIDEON Informatics, Inc. All rights reserved. Published by GIDEON Informatics, Inc, Los Angeles, California, USA. www.gideononline.com Cover design by GIDEON Informatics, Inc No part of this book may be reproduced or transmitted in any form or by any means without written permission from the publisher. Contact GIDEON Informatics at [email protected]. ISBN-13: 978-1-61755-068-3 ISBN-10: 1-61755-068-X Visit http://www.gideononline.com/ebooks/ for the up to date list of GIDEON ebooks. DISCLAIMER: Publisher assumes no liability to patients with respect to the actions of physicians, health care facilities and other users, and is not responsible for any injury, death or damage resulting from the use, misuse or interpretation of information obtained through this book. Therapeutic options listed are limited to published studies and reviews. Therapy should not be undertaken without a thorough assessment of the indications, contraindications and side effects of any prospective drug or intervention. Furthermore, the data for the book are largely derived from incidence and prevalence statistics whose accuracy will vary widely for individual diseases and countries. Changes in endemicity, incidence, and drugs of choice may occur. The list of drugs, infectious diseases and even country names will vary with time. Scope of Content: Disease designations may reflect a specific pathogen (ie, Adenovirus infection), generic pathology (Pneumonia – bacterial) or etiologic grouping(Coltiviruses – Old world). Such classification reflects the clinical approach to disease allocation in the Infectious Diseases Module of the GIDEON web application.
    [Show full text]
  • Legionellosis Investigation Form
    LEGIONELLOSIS INVESTIGATION FORM BASIC DEMOGRAPHIC DATA Last Name:________________________________ First Name:_______________________________ Middle Name:________________________ DOB: __ __ / __ __ /__ __ __ __ Age: _______ years months Current Sex: Female Male Unknown Is the patient deceased? No Unknown Yes Date of Death: __ __ / __ __ /__ __ __ __ Street Address 1:_____________________________________________________________ Street Address 2:______________________________ City:_______________________________________ State:_______ Zip Code:_______________ County:_______________________________ Home Phone: (__ __ __) ‐ __ __ __ ‐ __ __ __ __ Cell Phone: (__ __ __) ‐ __ __ __ ‐ __ __ __ __ Work Phone: (__ __ __) ‐ __ __ __ ‐ __ __ __ __ Ext. _______ Ethnicity: Hispanic or Latino Not Hispanic or Latino Unknown Race: American Indian/Alaska Native Asian Black/African American Native Hawaiian/Other Pacific Islander White Unknown INVESTIGATION SUMMARY Investigation Start Date: __ __ / __ __ /__ __ __ __ Investigation Status: Open Closed Investigator:__________________________________ REPORTING SOURCE Date of Report: __ __ / __ __ /__ __ __ __ Reporting Source:_______________________________________________________________________ CLINICAL Physician’s Name:_______________________________________________________ Phone Number: (__ __ __) ‐ __ __ __ ‐ __ __ __ __ Ext. _______ Was patient hospitalized for this illness? No Unknown Yes If yes: Hospital Name:_______________________________________________ Admission Date: __ __
    [Show full text]
  • Biological Role of Legionella Pneumophila Lipopolysaccharide
    Volume 4- Issue 1: 2018 DOI: 10.26717/BJSTR.2018.04.001003 Marta Palusinska Szysz. Biomed J Sci & Tech Res ISSN: 2574-1241 Mini Review Open Access Biological Role of Legionella Pneumophila lipopolysaccharide Marta Palusińska Szysz*1, Agata Wołczańska2 and Elżbieta Chmiel1 1Department of Genetics and Microbiology, Maria Curie-Sklodowska University, Poland 2Department of Botany and Mycology, Maria Curie-Sklodowska University, Poland Received: April 16, 2018; Published: April 26, 2018 *Corresponding author: Marta Palusinska Szysz, Faculty of Biology and Biotechnology, Institute of Microbiology and Biotechnology, Department of Genetics and Microbiology, Maria Curie-Sklodowska University, Akademicka 19 St., 20-033 Lublin, Poland Abstract bacteria which contributes to the cell surface properties in an exceptionally important way. The chemical structure of L. pneumophila LPS is differentThe lipopolysaccharidefrom that of the endotoxins (LPS) localized of other in Gram-negativethe outer membrane bacteria, is the despite predominant the similar molecule structure. on theDue cell to itssurface complex of Legionella structure pneumophila and function as well as immunochemical and antigen variability, the L. pneumophila LPS plays an important role in the interaction with the host cell. Introduction Legionella bacteria incapable of causing pneumonia in the affected Legionella pneumophila is an aquatic pathogen that is ubiquitously found in nature, both in anthropogenic structures infection is pneumonia, which does not require hospitalization. and in environmental waters as parasites of free living protozoa. host [8]. The most common clinical manifestation of Legionella Fatal courses of the disease occur when the bacteria disseminate In evolution with protozoa, L. pneumophila acquired a rare ability deeper into the lung. among microorganisms to infect macrophages owing to their The infection progresses from bronchopneumonia to lobar as one of the three most common causes of severe community- pneumonia.
    [Show full text]
  • INFECTIOUS DISEASES of HAITI Free
    INFECTIOUS DISEASES OF HAITI Free. Promotional use only - not for resale. Infectious Diseases of Haiti - 2010 edition Infectious Diseases of Haiti - 2010 edition Copyright © 2010 by GIDEON Informatics, Inc. All rights reserved. Published by GIDEON Informatics, Inc, Los Angeles, California, USA. www.gideononline.com Cover design by GIDEON Informatics, Inc No part of this book may be reproduced or transmitted in any form or by any means without written permission from the publisher. Contact GIDEON Informatics at [email protected]. ISBN-13: 978-1-61755-090-4 ISBN-10: 1-61755-090-6 Visit http://www.gideononline.com/ebooks/ for the up to date list of GIDEON ebooks. DISCLAIMER: Publisher assumes no liability to patients with respect to the actions of physicians, health care facilities and other users, and is not responsible for any injury, death or damage resulting from the use, misuse or interpretation of information obtained through this book. Therapeutic options listed are limited to published studies and reviews. Therapy should not be undertaken without a thorough assessment of the indications, contraindications and side effects of any prospective drug or intervention. Furthermore, the data for the book are largely derived from incidence and prevalence statistics whose accuracy will vary widely for individual diseases and countries. Changes in endemicity, incidence, and drugs of choice may occur. The list of drugs, infectious diseases and even country names will vary with time. © 2010 GIDEON Informatics, Inc. www.gideononline.com All Rights Reserved. Page 2 of 314 Free. Promotional use only - not for resale. Infectious Diseases of Haiti - 2010 edition Introduction: The GIDEON e-book series Infectious Diseases of Haiti is one in a series of GIDEON ebooks which summarize the status of individual infectious diseases, in every country of the world.
    [Show full text]